Healthcare companies rose, bucking the trend of the broader market, as traders sought out sectors less tied to the global economic outlook and interest rates.
One of the biggest addiction-drug makers is set to snatch up the owner of the U.S.'s bestselling overdose-reversal drug. U.K.-based Indivior said it would pay $20 per share, or about $145 million, to purchase Narcan-owner Opiant Pharmaceuticals.
Meanwhile, Moderna's new updated Covid-19 booster shot for the U.S. generated strong immune responses in people against Omicron subvariants, according to the first data from a company-sponsored study testing the new doses in volunteers.
An experimental Alzheimer's drug from Roche failed to significantly slow cognitive decline in long-awaited trials, the latest in a long line of setbacks for a field that has seen little progress in decades.
Write to Amy Pessetto at amy.pessetto@dowjones.com
(END) Dow Jones Newswires
11-14-22 1658ET
